ArticleCancers2021

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.

Nadia Harbeck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.